Cost Effectiveness of PD-L1-Based Test-and-Treat Strategy with Pembrolizumab as the First-Line Treatment for Metastatic NSCLC in Hong Kong

BACKGROUND: Pembrolizumab, a monoclonal antibody against programmed death ligand 1 (PD-L1), is approved by several regulatory agencies for first-line treatment of metastatic non-small-cell lung cancer (NSCLC) with a PD-L1 tumor proportion score (TPS) ≥ 50% and no epidermal growth factor receptor (EG...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Pharmacoecon Open
Autors principals: Loong, Herbert H., Wong, Carlos K. H., Leung, Linda Kam Suet, Dhankhar, Praveen, Insinga, Ralph P., Chandwani, Sheenu, Hsu, Danny C., Lee, Mary Y. K., Huang, Min, Pellissier, James, Rai, Akanksha, Achra, Monika, Tan, Seng Chuen
Format: Artigo
Idioma:Inglês
Publicat: Springer International Publishing 2019
Matèries:
Original Research Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7248157/
https://ncbi.nlm.nih.gov/pubmed/31531842
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s41669-019-00178-7
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars